Yungen Xu

29PUBLICATIONS
20CO-AUTHORS
Proteins and peptidesCheminformatics and quantitative structure-activity relationshipsBiologically active moleculesMolecular targetsPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (29)

|Apr 20, 2026
Discovery of Highly Potent Phthalazinone Derivatives as PARP14 Inhibitors: From Structure-Based Virtual Screening to In Vivo Pharmacodynamic Activity.

|Mar 31, 2026
Identification of an Orally Bioavailable Quinoline-Based Small-Molecule Tumor Necrosis Factor α (TNF-α) Inhibitor Featuring a Spirocyclic Scaffold.

Zeren Sun, Wenbin Zhang, Wanyong He

|Mar 07, 2026
Correction to "Discovery of Hydroxamic Acid Ester Derivatives as Second-Generation PRMT5 Inhibitors for the Treatment of Triple Negative Breast Cancer".

Xingxing Cheng, Zheqi Hu, Huihuan Mao

|Feb 25, 2026
Discovery of Novel and Potent Dual PARP1/ERK Inhibitors as a Promising Strategy for Cancer Therapy.

Ying Bai, Shiqi Wu, Wenhui Zhang

|Jan 29, 2026
Discovery of Novel Orally Bioavailable Polθ Inhibitors with Arylalkyne Scaffolds for Targeting HR-Deficient Cancers.

Jinyang Zhang, Xiaomeng Sun, Qichen Zhou

|Jan 13, 2026
Discovery of Oxime Ether Derivatives as Second-Generation PRMT5 Inhibitors for the Treatment of Triple Negative Breast Cancer.

Xingxing Cheng, Zheqi Hu, Huihuan Mao

Pageof 5

Frequent Collaborators

20 joint publications

Qihua Zhu

19 joint publications

Yi Zou

10 joint publications

Hongfeng Gu

3 joint publications

Jian Yang